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SHORT COMMUNICATION
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ABSTRACT
A retrospective study was performed in children (aged one month – 16 years) receiving HFNC to determine the frequency,
eﬃcacy and adverse eﬀects of high ﬂow nasal cannula (HFNC) therapy in the pediatric intensive care unit (PICU), from January
to December 2017. Treatment failure was deﬁned as clinical deterioration on HFNC therapy such that mechanical ventilation
(MV) was required. Clinical parameters before and after HFNC were assessed using repeated measures analysis of variance. A
total of 120 patients received HFNC therapy (21% of total admissions). Primary diagnosis were respiratory disease (50%),
central nervous system diseases (14.2%), sepsis (10.8%), and postoperative care (10%). Mean duration of HFNC was 27.5
±19.7 hours and mean PICU length of stay was 6 ± 6 days. Pneumothorax developed in four patients. MV was required in 28
patients, and subsequently, 15 deaths occurred in that group. HFNC is a frequently used, safe and eﬀective therapy for children
requiring respiratory support in PICU.
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Respiratory illnesses are one of the leading causes for pediatric
intensive care unit (PICU) admission (26.3%).1 Respiratory
support in PICU has evolved from predominantly mechanical
ventilation (MV) to non-invasive ventilation. This has markedly
reduced complications related to invasive mechanical ventilation.2,3 Heated, humidiﬁed, high-ﬂow nasal cannula (HFNC) is a
relatively new method of respiratory support.4 HFNC washes out
the carbon dioxide-rich gas in a portion of the anatomical dead
space and potentially provides positive airway pressure.
Humidiﬁcation saves energy spent warming and enables better
tolerance by decreasing the risk of nasal trauma.5 Previous clinical studies using HFNC therapy have shown a reduction in intubation rates in critically ill infants in PICU with a better safety
proﬁle.3,4,6
Correspondence to: Dr. Qalab Abbas, Department of Pediatrics and Child Health, The Aga Khan University
Hospital, National Stadium Road, Karachi, Pakistan
E-mail: qalababbas@gmail.com
.....................................................
Received: December 03, 2019; Revised: February 29, 2020;

Accepted: May 11, 2020
DOI: https://doi.org/10.29271/jcpsp.2021.01.110

110

We describe use of HFNC in our PICU. This study will pave the
path for larger studies on use of HFNC in children with acute
respiratory distress.
Retrospective review of medical records of children (aged one
month – 16 years) admitted in PICU of the Aga Khan University
Hospital and received HFNC, was done from January to
December 2017 after ethical approval (2019-1036-2634). The
decision to start HFNC was based on patients’ clinical condition
[respiratory distress deﬁned as increased respiratory rate,
increased work of breathing, oxygen saturation as per standard
pediatric advanced life support (PALS) guidelines], hemodynamic stability (age-appropriate normal heart rate, perfusion
and blood pressure as per PALS criteria), normal Glasgow coma
scale (GCS) and oxygen saturation (SaO2) and attending physician discretion. Patients with SaO2 <88% on pulse oximetry,
GCS <12, and hemodynamic instability were not provided
HFNC. HFNC was provided at the maximum rate of 2 litres/kilogramme body weight/minute, through Optiﬂow® system with
age appropriate nasal cannulas (Fisher and Paykel Healthcare).
HFNC was switched to O2 by nasal prongs, if patient was at <40%
FiO2 for more than 6 hours with stable vital signs and work of
breathing, and was labelled HFNC success.
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Table I: Comparison of variables between high ﬂow nasal cannula success and failure.
High ﬂow nasal cannula failure
High ﬂow nasal cannula success
(intubated)
(non-intubated)
n=28
n=92

Heart rate
0 hours (before start of HFNC)
At 2 hours of HFNC
At end of HFNC
Respiratory rate
0 hours (before start)
2 hours
End of HFNC
SaO2 / FiO2 ratio
Gender:
Male
Female

Independent t-test /
Chi-square test
p-value (95% CI)

Mean ± SD*
154 ± 21
135 ± 13
127.18 ± 26

Mean ± SD
145.6 ± 21
125.38 ± 21
115.11 ± 19

0.11
0.034
0.01

46.7 ± 13
39.6 ± 14
35.82 ± 18
210 ± 63.28

49.30 ± 12
35.37 ± 8
28.67 ± 8
217.56 ± 51.70

0.35
0.066
0.003
0.59

21
7

53
39

0.09, (0.85 – 5.71)

Admission source:
Emergency
Inpatient
Operating room
Cardiac ICU

20
7
0
1

53
30
8
1

Reason for admission:
Acute respiratory distress
acute respiratory failure
post-op care
Others (for monitoring)

3
22
0
3

38
32
12
10

Comorbids:
Yes
No

16
12

49
43

Diagnosis:
Central nervous system diseases
Cardiovascular diseases
Respiratory diseases
Gastrointestinal diseases
Infections
Malignancy
Surgical
Miscellaneous

3
5
14
1
3
0
1
1

14
6
46
0
10
1
11
4

19
9

86
6

Survival:
Yes
No
*SD = standard deviation.

If a patient had SaO 2 <88% on HFNC, FiO 2 requirements
>70%, respiratory distress or hemodynamic instability,
HFNC treatment was regarded as failure and MV was instituted. Patients were also observed for development of
complication (pneumothorax) detected on chest X-ray.
Data collection included demographic, clinical, and HFNC
details. Chi-square / T-test were applied to compare HFNC
success versus failure. A p-value of <0.05 was taken as
signiﬁcant.
A total of 120 patients met the inclusion criteria, making
21% of total PICU admissions. The primary diagnosis was
respiratory system diseases (60, 50%), central nervous
system diseases (17, 14.2%), sepsis (13, 10.8%), postoperative care (12, 10%) and miscellaneous (two patients with
acute kidney injury and severe diabetic ketoacidosis each
and one patient with severe malnutrition).

0.23

0.001

0.72 (0.49 – 2.75)

0.001 (0.047 – 0.46)

Mean HFNC duration was 27.5 ±19.7 hours, while mean PICU
length of stay was 6 ± 6 days. Twenty-eight patients
(23.3%) failed HFNC and required MV. Complication (pneumothorax) developed in four (3.3%) and all survived. Mean
heart rate and respiratory rate decreased signiﬁcantly in all
patients after two hours of HFNC therapy (p < 0.05, Table I).
This diﬀerence was more pronounced in patients in whom
HFNC was successful as compared to patients who failed
HFNC therapy (Table I). The SaO2 / FiO2 ratio was same in
both groups (p=0.59). Fifteen (12.5%) patients died, underlying cause was acute respiratory distress syndrome (ARDS)
in seven, acute heart failure in four, sepsis in two, and acute
leukemia with relapse in one.
HFNC is being increasingly used in children for a variety of
conditions.2 Recent studies have shown HFNC to be eﬀective
in infants with bronchiolitis, requiring less escalation of
therapy compared to standard therapy.6
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Escalation to MV (23%) in this study was higher than in
3,6
previous studies of 8-18%. Amongst patients who failed
HFNC, there were 15 deaths and failure of HFNC could be
due to the severity of presenting disease. However,
mechanical ventilation was not warranted at the start of
treatment in any of the patients and so there was clinical
equipoise as to the use of HFNC at this stage of disease
evolution, allowing us to determine our own criteria for its
use. This study did not consider the diagnosis-speciﬁc
failure rate.
Pneumothorax was the main complication observed in this
study. Previous report show frequency of <1% of development of pneumothorax with HFNC.3,6 Pneumothorax on HFNC
develops with severe underlying lung disease or due to
formation of seal around the nasal cannula due to thick
secretions or inappropriate nasal cannula size.
Pneumothorax was small in all these patients with no hemodynamic instability and spontaneous resolution in three, one
required chest drain insertion. It could be related to underlying disease process but further exploration into the cause
of pneumothorax was not possible because of type of study
design.

Heart rate and respiratory rate improved signiﬁcantly
within two hours of start of HFNC therapy in all the patients,
and this diﬀerence was signiﬁcant in patients with HFNC
success compared to those who failed the intervention. This
means that clinical status assessment after two hours of
starting HFNC therapy is important and can be a predictor
of HFNC therapy success. Further studies must be
performed to explore this. SaO2 and FiO2 ratio (a marker of
severity of hypoxia and disease) were similar in the both
the groups.
The study has limitations of being a single centre, retrospective and small sample size. Further studies may identify reliable cardiorespiratory and diagnostic predictors of therapy
failure. Despite that, HFNC is frequently used, safe and eﬀective therapy for children requiring respiratory support in
PICU.
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